Willem Hettema1, Christopher Wynne2, Benjamin Lang3, Mario Altendorfer4, Niklas Czeloth4, Ragna Lohmann5, Sandeep Athalye6, Dorothee Schliephake6. 1. a Translational Medicine and Clinical Pharmacology , Boehringer Ingelheim , Biberach an der Riß , Germany. 2. b Christchurch Clinical Studies Trust , Christchurch , New Zealand. 3. c Biostatics, Boehringer Ingelheim , Biberach an der Riß , Germany. 4. d Bioscience, Boehringer Ingelheim , Ingelheim , Germany. 5. e Clinical Operations, Boehringer Ingelheim , Ingelheim , Germany. 6. f Clinical Development, Boehringer Ingelheim , Ingelheim , Germany.
Abstract
OBJECTIVES: This Phase I trial (INVICTAN®-1) evaluated three-way bioequivalence and safety of BI 695502 a bevacizumab biosimilar candidate, and reference product bevacizumab from two sources (US-approved Avastin®, Genentech; EU-approved Avastin, Roche). METHODS:Healthy male subjects (N = 91) were randomized 1:1:1 to receive a single intravenous infusion of 1 mg/kg of BI 695502 or US- or EU-approved Avastin. An interim analysis was planned when ~50% of subjects were evaluable for the primary end point to determine if the prespecified criteria for bioequivalence were achieved; if demonstrated, the study could be stopped early. The primary end point was area under the concentration-time curve (AUC) of the analyte in plasma from time zero extrapolated to infinity (AUC0-∞). Other pharmacokinetic (PK) parameters, safety, and in vitro binding affinity were also evaluated. RESULTS: The interim analysis demonstrated three-way bioequivalence for all comparisons. The confidence intervals around the geometric mean ratios of the primary and secondary PK parameters were within the predefined acceptance ranges. Study drugs were well tolerated with no clinically relevant differences in safety. CONCLUSION:BI 695502 and US- and EU-approved Avastin showed three-way bioequivalence with similar safety profile. CLINICAL TRIAL REGISTRATION: NCT01608087.
RCT Entities:
OBJECTIVES: This Phase I trial (INVICTAN®-1) evaluated three-way bioequivalence and safety of BI 695502 a bevacizumab biosimilar candidate, and reference product bevacizumab from two sources (US-approved Avastin®, Genentech; EU-approved Avastin, Roche). METHODS: Healthy male subjects (N = 91) were randomized 1:1:1 to receive a single intravenous infusion of 1 mg/kg of BI 695502 or US- or EU-approved Avastin. An interim analysis was planned when ~50% of subjects were evaluable for the primary end point to determine if the prespecified criteria for bioequivalence were achieved; if demonstrated, the study could be stopped early. The primary end point was area under the concentration-time curve (AUC) of the analyte in plasma from time zero extrapolated to infinity (AUC0-∞). Other pharmacokinetic (PK) parameters, safety, and in vitro binding affinity were also evaluated. RESULTS: The interim analysis demonstrated three-way bioequivalence for all comparisons. The confidence intervals around the geometric mean ratios of the primary and secondary PK parameters were within the predefined acceptance ranges. Study drugs were well tolerated with no clinically relevant differences in safety. CONCLUSION:BI 695502 and US- and EU-approved Avastin showed three-way bioequivalence with similar safety profile. CLINICAL TRIAL REGISTRATION: NCT01608087.
Entities:
Keywords:
BI 695502; Bevacizumab; bioequivalence; biosimilar; pharmacokinetics
Authors: Joyson J Karakunnel; Nam Bui; Latha Palaniappan; Keith T Schmidt; Kenneth W Mahaffey; Briggs Morrison; William D Figg; Shivaani Kummar Journal: J Transl Med Date: 2018-12-04 Impact factor: 5.531
Authors: Takashi Eto; Yuji Karasuyama; Verónica González; Ana Del Campo García Journal: Cancer Chemother Pharmacol Date: 2021-07-16 Impact factor: 3.333